Oslo, March 28 2025. Navamedic ASA (OSE ticker "NAVA") has received a letter from the Norwegian Financial Supervisory Authority (the "NFSA") regarding the accounting of Navamedic's loans to Observe Medical ASA in relation to the Company's annual financial statements for 2023.

The NFSA's assessment is that there are misstatements in the annual financial statements for 2023 and in the interim financial statements for 2024 related to the Company's accounting of the two loans Navamedic has to Observe Medical ASA, interest on those loans and the information provided in the notes to the accounts.

The Company will assess the information received and implement any required corrections of the accounts.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic Mobile: +47 951 78 680 E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic Mobile: +47 917 62 842 E-mail: lars.hjarrand@navamedic.com

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to section 5-12 the Norwegian Securities Trading Act.

This stock exchange announcement was published by Lars Hjarrand, CFO of the Company, on 28 March 2025 at 14:24 hours CET on behalf of the Company.

About Navamedic:

Navamedic ASA is a Nordic pharmaceutical company dedicated to enhancing people's quality of life by being a reliable supplier of high-quality prescription, consumer health, and hospital products to hospitals and pharmacies. Our growing product portfolio has been carefully selected to meet current public health concerns, such as obesity, Parkinson's disease, antibiotics and metabolism, to empower people to live healthier and more fulfilling lives. What sets us apart is our deep-rooted commitment to understanding the needs and requirements of the countries where we are present. Our local insight and competence enable us to understand the specific needs of each country where we operate and ultimately to gain market access. This makes us a preferred partner for international companies expanding their footprint across the Nordics and Benelux regions, through either in-licensing or out-licensing. Navamedic has been listed on the Oslo Stock Exchange since 2006 (ticker: NAVA) and is headquartered in Oslo, Norway. For more information, please visit Navamedic.com.